Karo Bio AB Reports Positive Results for KB3305 in Diabetes Patients

STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News: Karo Bio’s (STO:KARO) compound KB3305, a liver selective antagonist for the glucocorticoid receptor, shows clinically relevant and statistically significant effects on plasma glucose levels in type 2 diabetes patients.
MORE ON THIS TOPIC